The document announces a market research report on Versartis, Inc.'s product pipeline in 2012 from Global Markets Direct. It provides an overview of Versartis' research focus and developmental pipeline at the time, including drug candidates in various stages of clinical trials for conditions like endocrine/metabolic disorders and cancer. The report also details four of Versartis' lead pipeline drugs - VRS-317, VRS-808, VRS-826, and VRS-859 + AMX-808 - and their descriptions, mechanisms of action, and development progress. Tables of contents and figures are included, as well as links to purchase the full report and other similar reports from Global Markets Direct.